dr. wakelee discusses egfr tkis in lung cancer
Published 6 years ago • 164 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
1:36
dr. heather wakelee on what to do when resistance to egfr tkis emerges
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:05
dr. wakelee on recent advancements in egfr-mutant nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
1:03
dr. wakelee discusses dacomitinib in egfr nsclc
-
1:13
dr. wakelee discusses the future of lung cancer adjuvant therapy
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
2:03
dr. west on considering factors for egfr tkis in nsclc
-
1:33
dr. wakelee on continued maintenance in lung cancer
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc
-
3:00
egfr-resistant disease in lung cancer
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:21
dr. wakelee on importance of ngs testing in nsclc
-
1:55
dr. heather wakelee discusses nintedanib plus chemotherapy in nsclc
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc